pentasaccharide

Browse trials
V2  
List  

treatment    comparator  All cause death Major bleeding Minor bleeding Symptomatic pulmonary embolism Deep vein thrombosis  proximal DVT  non-fatal pulmonary embolism  asymptomatic DVT  total VTE and all-cause mortality  Venous thromboembolism fatal pulmonary embolism  Symptomatic venous thromboembolism (DVT, PE) pulmonary embolism (symptomatic and asymptomatic)  Symptomatic deep-vein thrombosis major or clinically relevant non-major bleeding net benefit Venous thromboembolism or death proximal deep-vein thrombosis     
Fondaparinuxthrombosis prevention, in orthopedic surgery vs placebo------------------
Fondaparinuxthrombosis prevention, in orthopedic surgery vs enoxaparinNS by 38% -NS by 52% by 54% NS-- by 50% NSNS-NS----
Fondaparinuxthrombosis prevention, in abdominal surgery vs placebo (on top intermittent pneumatic comp.)NS by 924% -NS by 69% NS--- by 69% -NS------
Fondaparinuxthrombosis prevention, in abdominal surgery vs enoxaparinNSNS-NSNSNSNS--NSNSNS-NS----
Fondaparinuxthrombosis prevention, in medical patients vs placeboNSNS-NS---------NS----
Fondaparinuxthrombosis prevention, in all type of patients vs placebo------------------
Fondaparinuxthrombosis prevention, in all type of patients vs placebo (on top intermittent pneumatic comp.)NS by 924% -NS by 69% NS--- by 69% -NS------
Fondaparinuxthrombosis prevention, in all type of patients vs enoxaparinNS by 39% -NS by 48% by 50% NS-- by 46% NSNS-NS----